Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 |
| NCT06878664 | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors(RIALTO) | recruiting | Phase 3 | 166 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 2 | Sep 16, 2026 | clinicaltrials |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen(CAREFNDR) | recruiting | Phase 3 | 141 | Crinetics Pharmaceuticals Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT06784752 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET(NETTER-3) | recruiting | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT07813351 | PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours(PRESTO) | not yet recruiting | Phase 3 | 82 | University College, LondonOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | active not recruiting | Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT06091748 | Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07591493 | Adjuvant Trial in Pancreatic Neuroendocrine Tumors(ADJUPANET) | not yet recruiting | Phase 3 | 300 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT01744249 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | completed | Phase 2 / Phase 3 | 256 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Apr 28, 2026 | clinicaltrials |
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 2 / Phase 3 | 298 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT07463235 | Safety and Potency of a High Cabergoline Dosage in Microprolactinomas(SPARAGMOS) | recruiting | Phase 3 | 70 | University of Sao Paulo General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04706910 | 18F-DOPA II - PET Imaging Optimization | recruiting | Phase 3 | 800 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE(COMPOSE) | active not recruiting | Phase 3 | 259 | ITM Solucin GmbHINDUSTRY | 10 | Sep 10, 2025 | clinicaltrials |
| NCT05387603 | Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.(START-NET) | recruiting | Phase 3 | 300 | Lund University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05459844 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | active not recruiting | Phase 3 | 196 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT02840149 | SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors | completed | Phase 3 | 45 | Jewish General HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02246127 | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor(SEQTOR) | completed | Phase 3 | 141 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 8 | May 11, 2025 | clinicaltrials |
| NCT06855095 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial(ATSA) | recruiting | Phase 2 / Phase 3 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04847505 | 68Ga-DOTA-TATE PET/CT Imaging in NETs | unknown | Phase 3 | 5,000 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03136328 | Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan | completed | Phase 3 | 11 | Montefiore Medical CenterOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT00442533 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 200 | Radio Isotope Therapy of AmericaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | completed | Phase 3 | 219 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 195 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03673943 | Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE | completed | Phase 3 | 63 | Radiomedix, Inc.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT01842165 | 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs(LUMEN) | completed | Phase 3 | 37 | Jules Bordet InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03590119 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases(LUTIA) | completed | Phase 2 / Phase 3 | 26 | Marnix LamOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00842348 | Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour(NET729) | completed | Phase 3 | 89 | IpsenINDUSTRY | 9 | Oct 12, 2022 | clinicaltrials |
| NCT01578239 | A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours(NETTER-1) | completed | Phase 3 | 231 | Advanced Accelerator ApplicationsINDUSTRY | 8 | Apr 4, 2022 | clinicaltrials |
| NCT04552847 | Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 85 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03042416 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | completed | Phase 3 | 400 | University of AlbertaOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT00171873 | Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | completed | Phase 3 | 85 | Carmen Schade-BrittingerOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT00037869 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | completed | Phase 3 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00227136 | Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | terminated | Phase 3 | 8 | University of Western Ontario, CanadaOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03271918 | Cabergoline in Nonfunctioning Pituitary Adenomas | completed | Phase 3 | 140 | University of Sao Paulo General HospitalOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01755182 | Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors(LOTUS) | terminated | Phase 3 | 1 | National Cancer Institute, NaplesOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT01860742 | Randomized Phase III of PRRT Versus Interferon(CASTOR) | withdrawn | Phase 3 | 0 | Jules Bordet InstituteOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00412061 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor(RADIANT-2) | completed | Phase 3 | 429 | Novartis PharmaceuticalsINDUSTRY | 15 | Nov 21, 2014 | clinicaltrials |
| NCT01373736 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | unknown | Phase 3 | — | Vancouver Coastal HealthOTHER_GOV | 1 | Jun 15, 2011 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials